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Introduction
(Invitrogen). Immunoblotting was done with primary antibodies listed in supplementary information. After incubation with appropriate secondary antibodies, signal was detected using chemiluminescence and film or a FujiFilm Imager LAS-4000.
Cap-dependent Translation Assay
Cells were plated at 0.6 to 0.7 x 10 6 cells per mL in 15 mL media overnight before drug treatment for 3 h and lysis in 350 μL ice-cold RIPA lysis buffer containing protease and phosphatase inhibitors. Lysates were diluted to 1 μg/μL and 450 μL was added to 55 μL methyl-7-GTP sepharose beads (GE Healthcare) and rotated overnight at 4˚C. The beads were washed and bound proteins were eluted with 1X SDS buffer, heated to 95˚C and separated on Bis-Tris 4-12% gradient gels.
Polysome Profiling
OCI-M1 or EOL-1 cell lines were treated with DMSO or AZD1208 (1μM) for 9 hours and polysomal fractionation was performed as described in previous studies.
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In Vivo Studies 5-6 week old female CB17 SCID mice purchased from Charles River Labs were maintained under specific pathogen-free conditions and used in compliance with protocols approved by the Institutional Animal Care and Use Committees of AstraZeneca, which conform to institutional and national regulatory standards on experimental animal usage. For pharmacodynamic studies, mice with tumors of 200-400 mm 3 were treated with either vehicle or AZD1208, with three mice per dose and timepoint, and tumors harvested and lysed for immunoblot analysis. Phosphorylated BAD protein levels were quantified using the phospho/total-BAD MULTI-SPOT assay system from Meso Scale Discovery (MSD).
For pharmacokinetic analysis, blood samples were collected from the same mice via cardiac puncture. Total plasma concentrations of AZD1208 were determined by LC/MS/MS method.
Patient Samples
Bone marrow aspirates were obtained from newly diagnosed AML patients (Dana-Farber
Cancer Institute, Boston, MA) with patient consent and approval from the DFCI Institutional Review Board. This study was conducted in accordance with the Declaration of Helsinki. for Pim kinases and the next most potent "hit" in the panel (CDK7) was at least 43 fold.
To assess the potency of AZD1208 on each of the three Pim isoforms in a cell-based assay, a substrate-enzyme tethered system was engineered. Constructs were created with fulllength Pim-1,-2 and -3 kinases individually fused to a BAD peptide substrate via a flexible (G 4 S) 4 linker and a Myc tag at the N-terminus to allow capture in a sandwich ELISA. The 
Biomarker Modulation and Downstream Effects of AZD1208 in AML Cell Lines
In addition to BAD, Pims have been shown to play a role in phosphorylation of other proteins shared with the PI3K/AKT/mTOR signaling pathway, as shown in Figure 3A .
Modulation of several of these proteins was measured after treatment with AZD1208 in sensitive and resistant cell lines. Assessment of BAD phosphorylation on Ser 112 demonstrated inhibition by AZD1208 not only in MOLM-16 cells, but also in sensitive KG1a, Kasumi-3, and MV4-11 cells ( Figure 3B and Figure S1 ). However, no inhibition was observed in sensitive EOL-1 cells and varying degrees of inhibition were also seen in resistant cells, indicating that modulation of pBAD does not necessarily correlate with growth inhibition or apoptosis in these cell lines.
A better correlation with sensitivity to cell growth inhibition was seen for inhibition of phosphorylation of p70S6K on Thr 389 and its substrate the S6 ribosomal protein on Ser 235/236 ( Figure 3B and Figure S1 ). In addition, moderate suppression of p4EBP1 on Ser 65, and data not shown). The levels of total BAD, 4EBP1, p70S6K and S6 proteins were not reduced, although there was a slight reduction in total PRAS40 levels in two of the cell lines ( Figure S2 ). Increases in p27 were not seen in cell lines other than MOLM-16 (data not shown).
To assess the functional consequence of inhibition of 4EBP1 phosphorylation, the effect of AZD1208 on assembly of the cap-dependent translation complex was measured. Binding of unphosphorylated 4EBP1 to the cap binding protein eIF4E blocks its interaction with eIF4G, resulting in inhibition of cap-dependent translation, whereas phosphorylation of 4EBP1 inhibits binding to eIF4E and allows its interaction with eIF4G to promote translation
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. In response to AZD1208 treatment, three sensitive cell lines, MOLM-16, EOL-1 and KG-1a, showed reduced interaction of immunoprecipitated eIF4E with eIF4G and increased interaction with inhibitory 4EBP1 that correlated with reduced phosphorylation of 4EBP1 on Ser 65, most evident at the 1 μM dose ( Figure 3C ). The effects were much less marked in AZD1208 insensitive OCI-M1 cells.
To determine whether the observed inhibition of formation of translation initiation complexes manifests at the level of mRNA translation, polysome profiling was carried out.
Treatment with 1 μM AZD1208 resulted in marked suppression of polysomal peaks with a reciprocal increase in the 80S monosome peak in sensitive EOL-1 cells, but not in insensitive 
AZD1208 Efficacy and PK/PD in AML Xenografts
The in vivo activity of AZD1208 was assessed in a MOLM-16 xenograft model treated Figure 4D ). The total plasma drug concentration required to reach 50% inhibition of pBAD was 241 ng/mL, or 0.63 μM ( Figure 4D ).
AZD1208 was also tested in the KG-1a xenograft. Once daily treatment with 30 mg/kg resulted in 71% tumour growth inhibition at the end of the dosing period (day 39, Figure 4E ).
Treatment with the AML standard-of-care chemotherapeutic cytarabine (30 mg/kg twice weekly on consecutive days) resulted in 79% tumour growth inhibition. Combination of AZD1208 with cytarabine produced 96% tumor growth inhibition, and indication of a decreased rate of tumor regrowth following cessation of treatment ( Figure 4E ).
AZD1208 Activity in Primary AML Samples
Bone marrow aspirates obtained from newly diagnosed patients were used to evaluate the effects of AZD1208 on colony formation and Pim pathway biomarkers in primary AML cells. Mononuclear cells isolated from bone marrow aspirates were cultured in methylcellulose supplemented with cytokines and growth factors in the presence of increasing concentrations of AZD1208, cytarabine, or DMSO control for 14 days. Dosedependent inhibition of colony growth was seen, as shown for examples in Figure 5B .
Marked inhibition of colony formation (>60%) by 3 μM AZD1208 was seen in the majority of samples, including both FLT3 wild-type and ITD mutant samples, and was comparable to cytarabine in most samples ( Figure 5A ). Of the two samples which showed no growth inhibitory response to AZD1208, sample 020 was from a patient with acute promyelocytic leukemia, and sample 036 was uniquely resistant to colony growth inhibition by both AZD1208 and cytarabine.
Biomarker responses were also asessed in mononuclear cells treated for three hours with up to 3 μM AZD1208. The extent of inhibition of phosphorylation of BAD, 4EBP1 and p70S6K was evaluated by immunoblot analysis and summarized in Figure S4 . Inhibition of Figure S4 and data not shown).
Discussion
AZD1208 is an orally available Pim kinase inhibitor with an excellent selectivity profile, low nanomolar activity against all three Pim isoforms at the enzyme level and potent activity in cells (see also Dakin et al.
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). AZD1208 inhibited growth in AML cell lines and xenograft tumor models, both as monotherapy and in combination with the standard of care cytarabine.
AZD1208 also showed activity in ex vivo colony assays of progenitor cells from AML patients, where inhibition of colony growth was seen in the majority of samples tested. This , an mTORC1-dependent mechanism of Pim activity may be at least in part responsible for the inhibition of both p4EBP1 and p-p70S6K. One potential mechanism is through PRAS40, a known Pim substrate, but in our studies variable suppression of PRAS40 phosphorylation by AZD1208 was seen in both sensitive and insensitive cell lines.
Alternatively, Pims could regulate mTORC1 activity in AML through upstream regulation of the mTORC1 negative regulator pTSC2 (see Figure 3A) , as recently demonstrated in multiple myeloma models. 37 Ongoing preclinical and clinical analyses will be required to better understand the mechanism of action and context dependency of Pim kinase inhibition. The pan-Pim potency and selectivity of AZD1208 render it a particularly useful pharmacological tool for such studies. In addition, the activity of AZD1208 in multiple pre-clinical models of AML indicates its potential for therapeutic benefit in AML, and the ex vivo data demonstrates 
